Prognostic value of the lung immune prognostic index in metastatic gastric cancer: a single-center retrospective cohort study


GOKCEK S., Kanbur B., YETGİNOĞLU Ö., ARSLAN A. M., Uzun M., ÜNEK İ. T.

Future Oncology, cilt.22, sa.17, ss.2101-2108, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 17
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1080/14796694.2026.2704367
  • Dergi Adı: Future Oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE, Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
  • Sayfa Sayıları: ss.2101-2108
  • Anahtar Kelimeler: biomarkers, chemotherapy, Gastric cancer, immunotherapy, lung immune prognostic index, prognosis, systemic inflammation
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Aims: To evaluate the prognostic significance of the Lung Immune Prognostic Index (LIPI) in patients with metastatic gastric cancer (mGC). Patients and methods: We retrospectively analyzed 177 patients with mGC. Patients were stratified into three groups (good, intermediate, and poor) based on the LIPI score, which was calculated using a derived neutrophil-to-lymphocyte ratio (dNLR) >3 and lactate dehydrogenase (LDH) >upper limit of normal (ULN). Survival outcomes were analyzed using Kaplan–Meier and Cox regression models. Results: In univariate analyses, intermediate and poor LIPI, elevated dNLR and LDH, ECOG performance status ≥1, low albumin, and high CRP were significantly associated with overall survival. In multivariate analysis, poor LIPI remained an independent prognostic factor (HR: 3.43; 95% CI: 1.30–9.05; p = 0.013). ECOG performance status and C-reactive protein (CRP) were also independently associated with survival. Subgroup analysis showed a more pronounced prognostic impact of LIPI in Human Epidermal Growth Factor Receptor 2 (HER2)-negative patients. Conclusions: The LIPI is a simple, noninvasive, and inexpensive tool that provides strong prognostic information for patients with mGC, potentially aiding in better risk stratification in clinical practice.